 Sonia Flores
Concepts (392)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Simian Acquired Immunodeficiency Syndrome | 7 | 2017 | 90 | 1.690 |
Why?
| | HIV-1 | 11 | 2020 | 886 | 1.480 |
Why?
| | Hypertension, Pulmonary | 12 | 2017 | 1925 | 1.270 |
Why?
| | Lung | 17 | 2020 | 4107 | 1.100 |
Why?
| | Antimicrobial Cationic Peptides | 3 | 2020 | 82 | 1.010 |
Why?
| | Oxidative Stress | 11 | 2017 | 1318 | 0.970 |
Why?
| | Endothelium, Vascular | 8 | 2011 | 935 | 0.950 |
Why?
| | nef Gene Products, Human Immunodeficiency Virus | 6 | 2014 | 20 | 0.940 |
Why?
| | Simian Immunodeficiency Virus | 6 | 2017 | 91 | 0.920 |
Why?
| | Gene Products, tat | 4 | 2011 | 22 | 0.820 |
Why?
| | HIV Infections | 14 | 2020 | 2946 | 0.760 |
Why?
| | Macaca mulatta | 3 | 2017 | 186 | 0.680 |
Why?
| | Gene Products, nef | 3 | 2009 | 12 | 0.630 |
Why?
| | Superoxide Dismutase | 11 | 2005 | 352 | 0.610 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2020 | 201 | 0.540 |
Why?
| | Macaca | 5 | 2011 | 65 | 0.520 |
Why?
| | Cardiomegaly | 1 | 2017 | 168 | 0.500 |
Why?
| | Microbiota | 4 | 2017 | 760 | 0.480 |
Why?
| | Vascular Remodeling | 1 | 2017 | 192 | 0.480 |
Why?
| | Pulmonary Artery | 6 | 2020 | 1109 | 0.450 |
Why?
| | Calcifediol | 1 | 2014 | 33 | 0.430 |
Why?
| | Calcitriol | 1 | 2014 | 59 | 0.420 |
Why?
| | Golgi Apparatus | 2 | 2011 | 100 | 0.390 |
Why?
| | Diabetic Angiopathies | 3 | 2011 | 250 | 0.370 |
Why?
| | Cytokines | 4 | 2017 | 2084 | 0.370 |
Why?
| | Lipid Metabolism | 1 | 2015 | 523 | 0.360 |
Why?
| | Viral Regulatory and Accessory Proteins | 2 | 2012 | 28 | 0.340 |
Why?
| | Carotid Artery Diseases | 1 | 2011 | 61 | 0.340 |
Why?
| | Lipids | 1 | 2015 | 675 | 0.330 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2012 | 233 | 0.330 |
Why?
| | Societies, Scientific | 2 | 2020 | 51 | 0.330 |
Why?
| | Developed Countries | 1 | 2010 | 39 | 0.330 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2011 | 199 | 0.320 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2014 | 99 | 0.310 |
Why?
| | Diabetes Mellitus, Type 1 | 6 | 2011 | 3705 | 0.310 |
Why?
| | Anti-HIV Agents | 3 | 2020 | 837 | 0.300 |
Why?
| | DNA, Circular | 4 | 1990 | 15 | 0.300 |
Why?
| | Animals | 32 | 2020 | 37261 | 0.290 |
Why?
| | Sp1 Transcription Factor | 2 | 2005 | 25 | 0.280 |
Why?
| | Cathelicidins | 3 | 2020 | 42 | 0.270 |
Why?
| | Pulmonary Emphysema | 2 | 2016 | 311 | 0.260 |
Why?
| | Vascular Diseases | 1 | 2009 | 240 | 0.250 |
Why?
| | Research Personnel | 2 | 2020 | 183 | 0.250 |
Why?
| | HIV | 2 | 2017 | 246 | 0.240 |
Why?
| | NF-kappa B | 3 | 2011 | 678 | 0.240 |
Why?
| | Prostaglandins | 1 | 2005 | 101 | 0.230 |
Why?
| | T-Lymphocytes | 3 | 2011 | 1986 | 0.230 |
Why?
| | Bronchoalveolar Lavage Fluid | 4 | 2015 | 649 | 0.230 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 33 | 0.220 |
Why?
| | Chemokines, CXC | 1 | 2004 | 71 | 0.220 |
Why?
| | Hyperglycemia | 1 | 2008 | 358 | 0.220 |
Why?
| | Atherosclerosis | 1 | 2008 | 401 | 0.210 |
Why?
| | Lung Diseases | 3 | 2017 | 785 | 0.210 |
Why?
| | Autoimmune Diseases | 1 | 2007 | 455 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 385 | 0.200 |
Why?
| | NADPH Oxidases | 5 | 2007 | 140 | 0.190 |
Why?
| | Aspartic Acid | 1 | 2003 | 80 | 0.190 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 108 | 0.190 |
Why?
| | Virus Replication | 4 | 2012 | 527 | 0.190 |
Why?
| | Prediabetic State | 1 | 2005 | 248 | 0.190 |
Why?
| | Smoking | 2 | 2013 | 1610 | 0.190 |
Why?
| | Vasodilation | 1 | 2005 | 509 | 0.190 |
Why?
| | Autoimmunity | 1 | 2008 | 904 | 0.190 |
Why?
| | Endothelium | 3 | 2014 | 126 | 0.190 |
Why?
| | E-Selectin | 1 | 2002 | 56 | 0.180 |
Why?
| | Nitric Oxide | 4 | 2011 | 893 | 0.180 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4319 | 0.180 |
Why?
| | Humans | 40 | 2021 | 139072 | 0.180 |
Why?
| | Plasmids | 6 | 2005 | 359 | 0.170 |
Why?
| | Cohort Studies | 7 | 2020 | 5749 | 0.170 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2020 | 42 | 0.170 |
Why?
| | Viral Tropism | 1 | 2020 | 34 | 0.160 |
Why?
| | Repetitive Sequences, Nucleic Acid | 3 | 1990 | 114 | 0.160 |
Why?
| | Cultural Diversity | 1 | 2020 | 79 | 0.160 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 386 | 0.160 |
Why?
| | Immune Evasion | 1 | 2020 | 58 | 0.160 |
Why?
| | Hospital Medicine | 1 | 2021 | 89 | 0.150 |
Why?
| | Membrane Lipids | 1 | 2020 | 91 | 0.150 |
Why?
| | Awards and Prizes | 1 | 2020 | 72 | 0.150 |
Why?
| | Mice | 16 | 2013 | 17836 | 0.150 |
Why?
| | Mice, Inbred NOD | 4 | 2011 | 593 | 0.150 |
Why?
| | Career Choice | 1 | 2021 | 230 | 0.150 |
Why?
| | Phospholipids | 1 | 2020 | 219 | 0.140 |
Why?
| | Mouth | 2 | 2015 | 87 | 0.140 |
Why?
| | Apoptosis | 2 | 2007 | 2552 | 0.140 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 4 | 2011 | 24 | 0.140 |
Why?
| | Male | 21 | 2021 | 68299 | 0.140 |
Why?
| | Histocytochemistry | 1 | 2017 | 80 | 0.140 |
Why?
| | CD4 Lymphocyte Count | 3 | 2016 | 280 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1473 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 494 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 327 | 0.120 |
Why?
| | Transcription Factors | 1 | 2004 | 1701 | 0.120 |
Why?
| | Case-Control Studies | 3 | 2015 | 3577 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 220 | 0.120 |
Why?
| | Financing, Government | 1 | 2016 | 49 | 0.120 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 99 | 0.120 |
Why?
| | Education | 1 | 2016 | 110 | 0.120 |
Why?
| | Blotting, Western | 4 | 2005 | 1233 | 0.110 |
Why?
| | Mice, Inbred C57BL | 10 | 2013 | 5805 | 0.110 |
Why?
| | Hydrogen Peroxide | 2 | 2007 | 332 | 0.110 |
Why?
| | Liver | 5 | 2005 | 1807 | 0.110 |
Why?
| | Tyrosine | 2 | 2005 | 227 | 0.110 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 185 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 351 | 0.100 |
Why?
| | Intracellular Space | 1 | 2014 | 68 | 0.100 |
Why?
| | Cell Nucleus | 2 | 2009 | 608 | 0.100 |
Why?
| | Biota | 1 | 2013 | 35 | 0.100 |
Why?
| | Tropheryma | 1 | 2013 | 7 | 0.100 |
Why?
| | Whipple Disease | 1 | 2013 | 8 | 0.100 |
Why?
| | Clinical Competence | 1 | 2021 | 1151 | 0.100 |
Why?
| | Endothelial Cells | 4 | 2020 | 791 | 0.100 |
Why?
| | Pulmonary Medicine | 1 | 2014 | 82 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2014 | 2172 | 0.100 |
Why?
| | Phylogeny | 2 | 2020 | 1000 | 0.100 |
Why?
| | Female | 14 | 2021 | 74071 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1645 | 0.090 |
Why?
| | Inflammation | 4 | 2013 | 2853 | 0.090 |
Why?
| | Physicians | 1 | 2021 | 930 | 0.090 |
Why?
| | Metagenome | 1 | 2013 | 149 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1732 | 0.090 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2926 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2016 | 399 | 0.090 |
Why?
| | San Francisco | 1 | 2012 | 58 | 0.090 |
Why?
| | Global Health | 2 | 2017 | 382 | 0.090 |
Why?
| | Ischemia | 3 | 2005 | 414 | 0.090 |
Why?
| | Mice, SCID | 2 | 2011 | 368 | 0.090 |
Why?
| | Respiratory System | 1 | 2013 | 157 | 0.090 |
Why?
| | Dysbiosis | 1 | 2013 | 180 | 0.090 |
Why?
| | Reperfusion Injury | 2 | 2005 | 288 | 0.090 |
Why?
| | HeLa Cells | 2 | 2004 | 641 | 0.090 |
Why?
| | Mucin-5B | 1 | 2013 | 222 | 0.090 |
Why?
| | Odds Ratio | 1 | 2014 | 1084 | 0.090 |
Why?
| | Neointima | 1 | 2011 | 15 | 0.090 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 322 | 0.090 |
Why?
| | Rats | 4 | 2020 | 5594 | 0.090 |
Why?
| | Gastrointestinal Tract | 1 | 2013 | 203 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1748 | 0.080 |
Why?
| | Adoptive Transfer | 1 | 2011 | 222 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 357 | 0.080 |
Why?
| | Cells, Cultured | 5 | 2020 | 4183 | 0.080 |
Why?
| | Gene Transfer Techniques | 1 | 2011 | 176 | 0.080 |
Why?
| | DNA, Satellite | 1 | 1990 | 18 | 0.080 |
Why?
| | Exodeoxyribonucleases | 1 | 1990 | 22 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2004 | 2499 | 0.080 |
Why?
| | Biomedical Research | 1 | 2016 | 696 | 0.080 |
Why?
| | Vascular Resistance | 2 | 2009 | 364 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2005 | 276 | 0.080 |
Why?
| | Oxygen | 2 | 2005 | 977 | 0.080 |
Why?
| | Anti-Retroviral Agents | 1 | 2011 | 244 | 0.070 |
Why?
| | Spleen | 1 | 2011 | 524 | 0.070 |
Why?
| | Eisenmenger Complex | 1 | 2008 | 12 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2009 | 550 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 911 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1098 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 627 | 0.070 |
Why?
| | Transfection | 3 | 2005 | 942 | 0.070 |
Why?
| | Luciferases | 2 | 2005 | 150 | 0.070 |
Why?
| | Cell Line | 4 | 2011 | 2880 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 285 | 0.070 |
Why?
| | Kupffer Cells | 2 | 2004 | 49 | 0.070 |
Why?
| | Adult | 6 | 2020 | 38428 | 0.070 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2007 | 52 | 0.060 |
Why?
| | Bacteria | 1 | 2013 | 868 | 0.060 |
Why?
| | Minority Groups | 2 | 2021 | 275 | 0.060 |
Why?
| | Hypertrophy | 1 | 2007 | 136 | 0.060 |
Why?
| | Promoter Regions, Genetic | 4 | 2005 | 1235 | 0.060 |
Why?
| | Molecular Mimicry | 2 | 2003 | 42 | 0.060 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 5532 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2007 | 139 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2004 | 819 | 0.060 |
Why?
| | Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2005 | 3 | 0.060 |
Why?
| | Acetophenones | 1 | 2005 | 14 | 0.060 |
Why?
| | Onium Compounds | 1 | 2005 | 8 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 78 | 0.060 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2005 | 84 | 0.060 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 396 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 386 | 0.060 |
Why?
| | Acetylcholine | 1 | 2005 | 203 | 0.060 |
Why?
| | Sp3 Transcription Factor | 1 | 2004 | 6 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2005 | 1077 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1819 | 0.060 |
Why?
| | Middle Aged | 6 | 2020 | 33811 | 0.060 |
Why?
| | Chemokine CXCL1 | 1 | 2004 | 76 | 0.060 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2005 | 56 | 0.060 |
Why?
| | Blotting, Northern | 1 | 2004 | 198 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2005 | 206 | 0.050 |
Why?
| | Collagen | 1 | 2007 | 459 | 0.050 |
Why?
| | Heart | 1 | 1988 | 612 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2005 | 242 | 0.050 |
Why?
| | Free Radicals | 1 | 2004 | 114 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2007 | 513 | 0.050 |
Why?
| | Guanosine | 1 | 2003 | 41 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2004 | 88 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 142 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2004 | 232 | 0.050 |
Why?
| | Superoxides | 1 | 2004 | 217 | 0.050 |
Why?
| | Drosophila | 1 | 2004 | 152 | 0.050 |
Why?
| | Prevalence | 1 | 2010 | 2747 | 0.050 |
Why?
| | Neovascularization, Pathologic | 1 | 2005 | 296 | 0.050 |
Why?
| | Hepatocytes | 1 | 2004 | 211 | 0.050 |
Why?
| | Liver Circulation | 1 | 2002 | 11 | 0.050 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2003 | 49 | 0.050 |
Why?
| | Models, Chemical | 1 | 2004 | 270 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2009 | 1149 | 0.050 |
Why?
| | Aorta | 1 | 2005 | 416 | 0.050 |
Why?
| | Cell Line, Tumor | 3 | 2005 | 3399 | 0.050 |
Why?
| | Caspase Inhibitors | 1 | 2003 | 81 | 0.050 |
Why?
| | Mice, Inbred BALB C | 1 | 2005 | 1262 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2005 | 322 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 316 | 0.050 |
Why?
| | Hepacivirus | 1 | 2004 | 238 | 0.050 |
Why?
| | Aging | 2 | 1990 | 1857 | 0.050 |
Why?
| | Risk Factors | 3 | 2016 | 10390 | 0.050 |
Why?
| | Pyrroles | 1 | 2003 | 210 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 1003 | 0.050 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2002 | 87 | 0.050 |
Why?
| | Homeostasis | 1 | 2005 | 614 | 0.050 |
Why?
| | DNA | 2 | 2004 | 1441 | 0.040 |
Why?
| | Metalloporphyrins | 1 | 2002 | 105 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2003 | 230 | 0.040 |
Why?
| | Binding Sites | 1 | 2004 | 1317 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 56 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2008 | 2482 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 716 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2020 | 19 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2003 | 340 | 0.040 |
Why?
| | DNA, Bacterial | 2 | 2013 | 336 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 27 | 0.040 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2020 | 61 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 19 | 0.040 |
Why?
| | Sequence Analysis, DNA | 2 | 2013 | 824 | 0.040 |
Why?
| | Engineering | 1 | 2020 | 29 | 0.040 |
Why?
| | Receptors, CXCR4 | 1 | 2020 | 87 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2003 | 663 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2003 | 408 | 0.040 |
Why?
| | Speech | 1 | 2020 | 71 | 0.040 |
Why?
| | Coloring Agents | 2 | 2014 | 95 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2020 | 267 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2006 | 1103 | 0.040 |
Why?
| | Demography | 1 | 2020 | 298 | 0.040 |
Why?
| | Indoles | 1 | 2003 | 414 | 0.040 |
Why?
| | Transcriptional Activation | 3 | 2009 | 376 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1544 | 0.040 |
Why?
| | Travel | 1 | 2020 | 134 | 0.040 |
Why?
| | Virulence | 1 | 2020 | 265 | 0.040 |
Why?
| | Up-Regulation | 1 | 2002 | 853 | 0.040 |
Why?
| | Species Specificity | 1 | 2020 | 581 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1355 | 0.040 |
Why?
| | Mitochondria | 1 | 2005 | 958 | 0.040 |
Why?
| | Environment | 1 | 2020 | 340 | 0.040 |
Why?
| | Protein Binding | 1 | 2004 | 2235 | 0.040 |
Why?
| | Biomarkers | 2 | 2015 | 4095 | 0.040 |
Why?
| | Disease Progression | 1 | 2005 | 2752 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 514 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2021 | 290 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2011 | 200 | 0.030 |
Why?
| | Models, Biological | 3 | 2013 | 1810 | 0.030 |
Why?
| | Pneumonia | 1 | 2003 | 644 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1994 | 0.030 |
Why?
| | Leadership | 1 | 2021 | 394 | 0.030 |
Why?
| | Phenotype | 2 | 2020 | 3145 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 321 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 827 | 0.030 |
Why?
| | HIV Antigens | 1 | 2015 | 18 | 0.030 |
Why?
| | Genotype | 1 | 2020 | 1849 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2015 | 281 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2014 | 138 | 0.030 |
Why?
| | Nanotubes | 1 | 2014 | 47 | 0.030 |
Why?
| | Ear, Middle | 1 | 2013 | 84 | 0.030 |
Why?
| | Mucin 5AC | 1 | 2013 | 70 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 90 | 0.030 |
Why?
| | Myocardium | 2 | 1990 | 921 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2013 | 92 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 254 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1936 | 0.020 |
Why?
| | Cell Death | 1 | 2014 | 375 | 0.020 |
Why?
| | Cilia | 1 | 2013 | 172 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2014 | 228 | 0.020 |
Why?
| | Signal Transduction | 3 | 2014 | 5095 | 0.020 |
Why?
| | Cell Communication | 1 | 2014 | 316 | 0.020 |
Why?
| | Prospective Studies | 2 | 2015 | 7666 | 0.020 |
Why?
| | Phagocytosis | 1 | 2013 | 387 | 0.020 |
Why?
| | Reference Values | 1 | 2013 | 801 | 0.020 |
Why?
| | Bacterial Infections | 1 | 2013 | 245 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2011 | 31 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2013 | 554 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1193 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1148 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 87 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1311 | 0.020 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2011 | 128 | 0.020 |
Why?
| | Feces | 1 | 2013 | 486 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 1990 | 40 | 0.020 |
Why?
| | Genetic Markers | 1 | 2011 | 344 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 198 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 58 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2011 | 195 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 321 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 188 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 434 | 0.020 |
Why?
| | Chemokines, CX3C | 1 | 2009 | 10 | 0.020 |
Why?
| | Protein Transport | 1 | 2011 | 444 | 0.020 |
Why?
| | Chemokine CCL5 | 1 | 2009 | 43 | 0.020 |
Why?
| | Immunoblotting | 1 | 1990 | 309 | 0.020 |
Why?
| | Organ Specificity | 1 | 1990 | 310 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2009 | 93 | 0.020 |
Why?
| | Time Factors | 3 | 2005 | 6869 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2009 | 121 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 636 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2009 | 147 | 0.020 |
Why?
| | Nucleic Acid Renaturation | 1 | 1988 | 7 | 0.020 |
Why?
| | Nucleic Acid Denaturation | 1 | 1988 | 32 | 0.020 |
Why?
| | Scleroderma, Systemic | 1 | 2009 | 122 | 0.020 |
Why?
| | Echocardiography | 1 | 2011 | 638 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 280 | 0.020 |
Why?
| | Cattle | 1 | 2011 | 991 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2004 | 1244 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 611 | 0.020 |
Why?
| | Genes | 1 | 1988 | 227 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2011 | 528 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 626 | 0.020 |
Why?
| | DNA Transposable Elements | 1 | 1987 | 118 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1034 | 0.020 |
Why?
| | Brain | 2 | 1990 | 2794 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3990 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2854 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1045 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2697 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 593 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 2005 | 79 | 0.010 |
Why?
| | Fluoresceins | 1 | 2005 | 49 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2005 | 145 | 0.010 |
Why?
| | Chick Embryo | 1 | 2005 | 131 | 0.010 |
Why?
| | Phosphatidylinositol Phosphates | 1 | 2005 | 39 | 0.010 |
Why?
| | Catalase | 1 | 2005 | 134 | 0.010 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 174 | 0.010 |
Why?
| | Digitonin | 1 | 2004 | 5 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2005 | 274 | 0.010 |
Why?
| | Replicon | 1 | 2004 | 14 | 0.010 |
Why?
| | Survival | 1 | 2004 | 39 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2004 | 57 | 0.010 |
Why?
| | Microscopy, Confocal | 1 | 2005 | 324 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 159 | 0.010 |
Why?
| | Arachidonic Acids | 1 | 2003 | 63 | 0.010 |
Why?
| | PTEN Phosphohydrolase | 1 | 2005 | 163 | 0.010 |
Why?
| | Viral Nonstructural Proteins | 1 | 2004 | 65 | 0.010 |
Why?
| | Carrageenan | 1 | 2003 | 8 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 280 | 0.010 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 145 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2005 | 368 | 0.010 |
Why?
| | I-kappa B Proteins | 1 | 2003 | 76 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2003 | 85 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 442 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 862 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2002 | 19 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 182 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2002 | 147 | 0.010 |
Why?
| | Edema | 1 | 2003 | 129 | 0.010 |
Why?
| | Insulinoma | 1 | 2002 | 27 | 0.010 |
Why?
| | Extremities | 1 | 2003 | 139 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1150 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2005 | 339 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 2002 | 157 | 0.010 |
Why?
| | Clone Cells | 1 | 2002 | 265 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2005 | 621 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2002 | 225 | 0.010 |
Why?
| | Asthma | 1 | 2013 | 1894 | 0.010 |
Why?
| | Heparin | 1 | 2003 | 258 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7686 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 151 | 0.010 |
Why?
| | Hepatectomy | 1 | 2002 | 240 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 850 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 794 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2002 | 710 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2176 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 2005 | 719 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2003 | 966 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1471 | 0.010 |
Why?
| | United States | 1 | 2016 | 15078 | 0.010 |
Why?
| | Phosphorylation | 1 | 2003 | 1767 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2002 | 787 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2002 | 888 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2153 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 719 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2003 | 792 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2818 | 0.010 |
Why?
| | Neutrophils | 1 | 2003 | 1274 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 13378 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2853 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 21594 | 0.010 |
Why?
| | Aged | 1 | 2013 | 24186 | 0.010 |
Why?
|
|
Flores's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|